MYX announces acquisition of US generic product portfolio
Filed with ASX · · 8 pages · English
Watch Mayne Pharma's latest callMayne Pharma Group (ASX:MYX) Q4 2026 Earnings Call · Replay · Aug 26
Mayne Pharma Group Ltd. on 6ix
In the deck
Story so far
Earlier from Mayne Pharma
- MYX receives first generic approval of Tikosyn capsules
- Mayne Pharma receives FDA approval for Doryx MPC tablets
- 2015 Appendix 4E & Annual Report
- US Sales of Doryx Update
- US Oxycodone franchise restructure and Doryx re-launch
Later from Mayne Pharma
- Completion institutional entitlement offer and placement
- MYX announces settlement from patent infringement case
- MYX announces acquisition of US foam dermatology assets
- Appendix 4E, Directors Report and Financial Statements
- MYX launches generic Entocort EC (Budesonide) capsules
Follow Mayne Pharma into a list and get an email when it puts out news.
Follow Mayne Pharma